Atrophic vulvovaginitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:59 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Atrophic vulvovaginitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Estriol Vaginal Ring for Treating Vaginal Atrophy in Postmenopausal Women https://clinicaltrials.eu/trial/study-on-estriol-vaginal-ring-for-treating-vaginal-atrophy-in-postmenopausal-women/ Wed, 29 Apr 2026 15:05:55 +0000 https://clinicaltrials.eu/trial/study-on-estriol-vaginal-ring-for-treating-vaginal-atrophy-in-postmenopausal-women/ This clinical trial is focused on studying the effects of a new treatment for vaginal atrophy, a condition often experienced by postmenopausal women where the vaginal walls become thin, dry, and inflamed. The study will test a newly developed vaginal ring that releases estriol, a form of estrogen, in three different doses: 1 microgram per day, 10 micrograms per day, and 20 micrograms per day. There will also be a group using a placebo vaginal ring, which does not contain any active drug.

The purpose of the study is to evaluate how these different doses of estriol affect the vaginal tissue and pH levels over a period of 90 days. Participants will be randomly assigned to one of the treatment groups or the placebo group. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment until the study is completed. This helps ensure that the results are not biased.

Throughout the study, changes in the vaginal tissue and pH levels will be monitored to assess the effectiveness of the treatment. Additionally, a subgroup of participants will have their systemic exposure to estriol measured to understand how the body absorbs and processes the hormone. The trial aims to provide valuable information on the potential benefits of using estriol-releasing vaginal rings for treating vaginal atrophy in postmenopausal women.

]]> Study on the Effects of Vaginal Estrogen Treatment with Nomegestrol Acetate and Estradiol Hemihydrate on Blood Clotting in Postmenopausal Women with Vaginal Atrophy https://clinicaltrials.eu/trial/study-on-the-effects-of-vaginal-estrogen-treatment-with-nomegestrol-acetate-and-estradiol-hemihydrate-on-blood-clotting-in-postmenopausal-women-with-vaginal-atrophy/ Wed, 29 Apr 2026 15:04:09 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-vaginal-estrogen-treatment-with-nomegestrol-acetate-and-estradiol-hemihydrate-on-blood-clotting-in-postmenopausal-women-with-vaginal-atrophy/ This clinical trial is focused on studying the effects of a treatment for vaginal atrophy, a condition that often affects postmenopausal women. The treatment being tested involves the use of local vaginal estrogen, specifically a combination of two substances: nomegestrol acetate and estradiol hemihydrate. These substances are chemically similar to the hormones naturally found in the body and are used to help alleviate symptoms associated with vaginal atrophy.

The purpose of the study is to understand how this treatment affects the balance of blood clotting and breakdown in the body, known as the hemostatic balance. This is important because changes in this balance can affect the risk of blood clots. The study will involve postmenopausal women who will receive the treatment for a period of three months. During this time, researchers will monitor changes in blood clotting and breakdown processes to see if the treatment has any significant effects.

Participants in the study will receive the treatment at least three times a week. The study aims to compare the effects of the treatment on women with and without a history of venous thromboembolism (VTE), which is a condition where blood clots form in the veins. By the end of the study, researchers hope to gather valuable information on how local vaginal estrogen treatment influences blood clotting and breakdown in postmenopausal women.

]]> Study on Vaginal Tamoxifen for Improving Sexual Function in Women with Breast Cancer Experiencing Vulvovaginal Atrophy Symptoms https://clinicaltrials.eu/trial/study-on-vaginal-tamoxifen-for-improving-sexual-function-in-women-with-breast-cancer-experiencing-vulvovaginal-atrophy-symptoms/ Wed, 29 Apr 2026 15:00:02 +0000 https://clinicaltrials.eu/trial/study-on-vaginal-tamoxifen-for-improving-sexual-function-in-women-with-breast-cancer-experiencing-vulvovaginal-atrophy-symptoms/ This clinical trial is focused on studying the effects of a treatment for women with breast cancer who experience symptoms of vulvovaginal atrophy. Vulvovaginal atrophy is a condition that can cause discomfort in the vaginal area, often affecting sexual function. The treatment being tested is a medication called tamoxifen citrate, which is administered vaginally. Tamoxifen is a type of medication known as a selective estrogen receptor modulator, which means it can block or activate estrogen receptors in different tissues.

The purpose of the study is to evaluate how effective vaginal tamoxifen is in reducing the most bothersome symptoms of vulvovaginal atrophy in women with breast cancer. Participants in the study will be randomly assigned to receive either the tamoxifen treatment or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not biased. The study will last for a period of 12 weeks, during which participants will be monitored for changes in their symptoms and overall quality of life.

Throughout the study, participants will be asked to complete questionnaires that assess their symptoms and quality of life. These questionnaires include the Endocrine Subscale-FACT-B, which is specifically designed for breast cancer research, and other tools like the Female Sexual Function Index and the Female Sexual Distress Scale-revised. The information gathered will help researchers understand the impact of tamoxifen on sexual function and quality of life in women with breast cancer experiencing vulvovaginal atrophy.

]]>